Double attack on lymphoma: antibody plus CAR-T combo shows promise
NCT ID NCT06464185
First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T cells, which are specially engineered immune cells. The goal is to see if this combination is safe and improves response rates. About 48 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Obinutuzumab, Glofitamab, and CD19-CAR T cells
- What this could lead to
- If successful, this could offer a more effective treatment option for patients with hard-to-treat B-cell lymphoma that has returned after prior therapies.
- What could go wrong
- This is an early-phase trial with only 48 participants, so results may not apply broadly. The combination therapy carries risks of serious side effects like immune reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?